key: cord-0729443-1ooekpow
authors: Nägele, Matthias P.; Haubner, Bernhard; Tanner, Felix C.; Ruschitzka, Frank; Flammer, Andreas J.
title: Endothelial dysfunction in COVID-19: Current findings and therapeutic implications
date: 2020-10-14
journal: Atherosclerosis
DOI: 10.1016/j.atherosclerosis.2020.10.014
sha: dff949c5768384e17663c0dd1d15eabbaf120d56
doc_id: 729443
cord_uid: 1ooekpow

Coronavirus disease 2019 (COVID-19) increases the risk of several non-pulmonary complications such as acute myocardial injury, renal failure or thromboembolic events. A possible unifying explanation for these phenomena may be the presence of profound endothelial dysfunction and injury. This review provides an overview on the association of endothelial dysfunction with COVID-19 and its therapeutic implications. Endothelial dysfunction is a common feature of the key comorbidities that increase risk for severe COVID-19 such as hypertension, obesity, diabetes mellitus, coronary artery disease or heart failure. Preliminary studies indicate that vascular endothelial cells can be infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and evidence of widespread endothelial injury and inflammation is found in advanced cases of COVID-19. Prior evidence has established the crucial role of endothelial cells in maintaining and regulating vascular homeostasis and blood coagulation. Aggravation of endothelial dysfunction in COVID-19 may therefore impair organ perfusion and cause a procoagulatory state resulting in both macro- and microvascular thrombotic events. Angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and statins are known to improve endothelial dysfunction. Data from smaller observational studies and other viral infections suggests a possible beneficial effect in COVID-19. Other treatments that are currently under investigation for COVID-19 may also act by improving endothelial dysfunction in patients. Focusing therapies on preventing and improving endothelial dysfunction could improve outcomes in COVID-19. Several clinical trials are currently underway to explore this concept.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is significantly affecting socioeconomic and healthcare systems worldwide. The pathophysiology of its associated disease, coronavirus disease 2019 (COVID- 19) , is still largely unclear and under active investigation. This article provides an overview on recent evidence linking endothelial dysfunction with COVID-19 and its potential implications for preventing adverse outcomes and treating the disease.

Preliminary studies indicate that patients with cardiovascular risk factors and/or established cardiovascular disease have the highest risk of being hospitalized with COVID-19 and developing a more severe disease course. These risk factors include older age (>65 years), hypertension, obesity, diabetes mellitus, chronic lung disease, coronary artery disease and heart failure. [1] [2] [3] [4] Interestingly, a common denominator of all these cardiometabolic diseases is endothelial dysfunction. The endothelium is crucial for maintaining vascular tone and homeostasisdysfunction is associated with vasoconstriction, inflammation, permeability, and coagulation.

It is associated with major risk factors such as age, hypertension, diabetes mellitus, and obesity, as well as development and progression of cardiovascular diseases. 5 Classically, endothelial function is assessed by measuring the dilatation of brachial or coronary arteries in response to shear stress or external stimuli. 6 Newer methods also allow the assessment of smaller vascular beds such as the retinal microcirculation. 7

The primary site of infection in COVID-19 is the upper and lower respiratory tract. There, SARS-CoV-2 infects goblet secretory cells of the nasal mucosa and alveolar type II pneumocytes by binding to membrane-bound angiotensin-converting enzyme 2 (ACE2). 8 After priming of the virus spike protein and cleavage of ACE2 by the human protease TMPRSS2, the virus is internalized into the cell and viral replication begins. In severe COVID-19, there is a progressive infection of alveolar pneumocytes with significant viral shedding resulting in apoptosis and necrosis. 9 Interferon-mediated upregulation of ACE2 may facilitate infection of adjacent pneumocytes. 8 The subsequent immune reaction leads to progressive interstitial and alveolar edema, which impairs gas exchange and may eventually result in acute respiratory distress syndrome (ARDS).

Already shortly after the outbreak, reports suggested that COVID-19 affects other organs beyond the lung, most importantly the heart and kidney. 10, 11 In severe COVID-19, evidence of acute myocardial injury (elevation of cardiac troponins) is common, and is associated with impaired prognosis. In light of the tissue tropism of SARS-CoV-2 for ACE2-expressing cells, another major organ of the body is an important target of infection: the vascular endothelium.

Indeed, ACE2 is expressed abundantly on vascular endothelial cells of both small and large arteries and veins. We recently demonstrated viral inclusion structures within endothelial cells of glomerular capillary loops and signs of widespread endotheliitis in the heart, lung, kidney, liver and gastrointestinal tract in pathological specimens from 3 patients with severe COVID-19. 12 Endothelial injury and dysfunction may be the result of direct infection by SARS-CoV-2 (e.g. by inducing intracellular oxidative stress 13 ) as well as due to the profound systemic inflammatory response. In light of the potential association of COVID-19 with endothelial injury, it seems plausible that patients with preexisting endothelial dysfunction are vulnerable J o u r n a l P r e -p r o o f 5 to a more severe disease course given the crucial role of endothelial cells for vascular homeostasis and organ perfusion.

Systemic endotheliitis can explain end-organ damage in severe COVID-19. In a case series from New York, 14 one third of COVID-19 patients with electrocardiographic signs of active ischemia showed non-obstructive coronary artery disease, and thus microvascular dysfunction as a likely cause of ischemia. Myocardial inflammation as evidenced by increased cardiac troponins or magnet resonance imaging abnormalities is not uncommon in severe COVID-19. 15, 16 SARS-CoV-2 has been isolated from cardiac autopsy samples, however, this was not regularly associated with an infiltration of immune cells as seen in myocarditis. 17 The virus may rather affect the endothelium leading to secondary myocardial inflammation and dysfunction. The phenotype of myocardial dysfunction and ischemic electrocardiographic features in the absence of coronary obstruction or myocarditis is reminiscent of Takotsubo syndrome, which is also associated with endothelial dysfunction. 18 Vascular endothelial cells play a critical role in vascular homeostasis and the coagulation system. While healthy endothelial cells naturally express factors that induce vascular relaxation and increase blood flow, inhibit platelet aggregation and coagulation, and promote fibrinolysis, dysfunctional endothelial cells shift the balance towards vascular contraction and thrombus formation. 19 Most cardiovascular risk factors indeed cause a decreased endothelial production of vasorelaxing and antithrombotic mediators and a concomitantly increased formation of contracting and prothrombotic factors. 20 In severe COVID-19, markers of both endothelial and platelet activation are increased compared to controls. 21 Extensive microthrombosis promoted and aggravated by endothelial dysfunction could explain the profound elevation of D-dimers and thrombocytopenia in severe COVID-19. 3 In line with 6 these haematologic findings, recent reports show increased risk of both venous and arterial thrombotic events in COVID-19. 22, 23 A recent case series also suggested that pulmonary microthrombi and pulmonary endothelial dysfunction explain the unusual dead-space and shunt physiology found in severe COVID-19 patients. 24 Indeed, significant pulmonary endotheliitis, microvascular thrombosis and evidence of pulmonary endothelial infection by SARS-CoV2 was observed in another pathological case series. 25 Pulmonary microvascular dysfunction may therefore be an underlying mechanism behind the phenomenon of severe hypoxia despite relatively preserved lung mechanics in COVID-19. 26 In children with COVID-19-associated chilblains of the extremities, profound endothelial inflammation along with endothelial infection with SARS-CoV2 was observed in a small case series. 27

Most therapies under active investigation for COVID-19 focus on inhibition of viral replication and suppression of the excessive immune response. However, in light of the above, treatment of endothelial dysfunction is a promising approach to protect vulnerable 

Angiotensin II is a well-known mediator of endothelial dysfunction, which is in part mediated by increased oxidative stress following angiotensin II receptor type 1 activation. 29 Indeed, J o u r n a l P r e -p r o o f both ACE inhibitors and angiotensin receptor blockers (ARBs) have been shown to improve endothelial dysfunction. 30, 31 They may also attenuate procoagulatory states by reducing the expression of tissue factor in endothelial cells and other cell types. 32 The use of RAS inhibitors is not without controversy in COVID-19: They are associated with an upregulation of ACE2, which may (theoretically) increase susceptibility to infection. However, ACE2 is a part of the natural host response against pulmonary infections 33 and antagonizes RAS activation by hydrolysis of angiotensin II into angiotensin (1-7), a vasodilator with antioxidant and anti-inflammatory effects. 34 ACE2 is downregulated after invasion of SARS-CoV-2 into cells. This may lead to unopposed RAS activation resulting in endothelial injury and a pro-inflammatory and pro-thrombotic state in COVID-19 -which may be amendable by pharmacological RAS blockade. 35 Indeed, the use of RAS inhibitors was not associated with a higher risk of SARS-CoV-2 infection or an adverse outcome in recent observational studies. [36] [37] [38] [39] In a Spanish population-based study, a borderline-significant reduced risk for COVID-19 hospital admissions was found with ACE inhibitors and a lower risk for patients with diabetes who were treated with RAS inhibitors vs. non-users. 40 A trend of lower COVID-19-related mortality with RAS inhibitors was also found in a meta-analysis of four studies. 41 In a UK cohort study, RAS inhibitors were associated with a lower risk of COVID-19. 42 Recently, results from the first randomized trial on this topic were presented (BRACE-CORONA). 43 In this trial, discontinuation of RAS inhibitors in hospitalized patients with COVID-19 had no beneficial effect compared to continuation of therapy. Therefore, it is with ACE inhibitors and ARBs currently explore this hypothesis ( Table 1 and   Supplementary Table 1 ).

Statins are another promising drug class for treating endothelial dysfunction and preventing vascular damage in COVID-19. Similar to RAS inhibitors, statins improve endothelial function in patients with or at risk for cardiovascular disease. 44 activation. 46 We previously showed that statins improve endothelial dysfunction in rheumatoid arthritis, 49 suggesting that they may be particularly helpful in inflammatory conditions characterized by endothelial dysfunction. Some evidence points toward a beneficial effect in viral pneumonias such as influenza. 50 Larger studies on the effects of statins in COVID-19 are still pending. A small observational study in elderly nursing home subjects suggested a higher chance of a symptom-free COVID-19 infection in statin-users vs. non-users. 39 In a retrospective cohort study in China, statin use was associated with lower mortality compared to non-use in COVID-19. 51 Several intervention studies studying the role of statins in COVID-19 have recently been announced (Supplementary Table 1 ). Until then, it seems prudent to continue statins in COVID-19 patients who already received the drugs before infection and initiate statins in all patients who meet cardiovascular guideline-criteria supporting their use.

Several anti-inflammatory therapies under investigation for COVID-19 may partly act by improving endothelial function. For example, improvement of endothelial dysfunction has been described for tumor necrosis factor alpha inhibitors 52 or anti-IL-6 receptor antibodies. 53

Beyond drug therapies, the importance of effective preventive measures cannot be overstated during the current pandemic. In that regard, improving or maintaining a normal endothelial function by well-established lifestyle measures (i.e. keeping a normal weight, regular physical activity, abstaining from smoking and consuming a healthy and nutritious diet) may be helpful to reduce the risk of COVID-19. Specific supplemental interventions that reduce endothelial dysfunction (e.g. antioxidants 54 , flavanols 55 ) could also be considered for further testing. Of note, several trials studying the effects of vitamin C, antioxidants and polyphenols in COVID-19 have been started (Supplementary Table 1 increases reactive oxygen species (ROS) and activates nuclear factor kappa B (NF-kB), which inactivates nitric oxide (NO) to peroxynitrite and reduces its production by uncoupling endothelial NO synthase (eNOS). (4) Activation of several cytokine receptors (e.g. tumor necrosis factor alpha receptor, interleukin 6 receptor) can directly or indirectly impair endothelial function. Endothelial dysfunction in turn impairs organ perfusion by disrupting the balance between vasoconstriction and dilatation, increases inflammation and leads to a pro-thrombotic state in both larger and smaller vessels, such as by increasing tissue factor and favoring platelet activation. This vicious cycle may be amendable by treatments targeting different steps of the cascade, such as ACE inhibitors, angiotensin receptor blockers (ARBs), cytokine inhibitors (e.g. interleukin 6 receptor antibodies) or statins. Statins may be helpful by reducing oxidized LDL levels and NADPH oxidase activity, which decrease reactive oxygen species (ROS), directly or indirectly affecting the transcription of NF-kB or by improving coupling of eNOS. Measures to prevent and treat important comorbidities could also be helpful along with selected supplements such as antioxidants. 

Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 -United States

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

Endothelial function and dysfunction

Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension

The assessment of endothelial function: from research into clinical practice

Retinal microvascular dysfunction in heart failure

SARS-CoV-2 Receptor ACE2 Is an

Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues

Pathogenesis of COVID-19 from a cell biology perspective

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Acute kidney injury in SARS-CoV-2 infected patients

Endothelial cell infection and endotheliitis in COVID-19

Redox Biology of Respiratory Viral Infections

ST-Segment Elevation in Patients with Covid-19 -A Case Series

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)

Management of acute myocardial injury in patients with confirmed or suspected COVID-19

Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases

Endothelial function and sympathetic nervous system activity in patients with Takotsubo syndrome

Endothelial cell control of thrombosis

Carbamylated Low-Density Lipoproteins Induce a Prothrombotic State Via LOX-1: Impact on Arterial Thrombus Formation In Vivo

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

COVID-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome

SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases

Targeting vascular (endothelial) dysfunction

Oxidative stress-mediated effects of angiotensin II in the cardiovascular system

Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials

Angiotensin II receptor blockers improve peripheral endothelial function: a meta-analysis of randomized controlled trials

Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy

A Dynamic Variation of Pulmonary ACE2 Is Required to Modulate Neutrophilic Inflammation in Response to Pseudomonas aeruginosa Lung Infection in Mice

The ACE2/Angiotensin

The pivotal link between ACE2 deficiency and SARS-CoV-2 infection

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19

Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality

Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis

The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents

Use of renin-angiotensinaldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a casepopulation study

Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study

Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people

Continuing vs. Suspending ACE Inhibitors and ARBs in COVID-19 In

Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials

Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein

Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering

Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy

Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways

Simvastatin improves endothelial function in patients with rheumatoid arthritis

Pandemic influenza: a potential role for statins in treatment and prophylaxis

In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19

Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis

Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation

New evidence implicates endothelial dysfunction in the pathophysiology of COVID-19

It may explain complications such as multi-organ damage or thrombotic events

Targeted interventions such as RAS inhibitors or statins may improve outcomes

Studies on interventions that affect endothelial dysfunction are underway in COVID-19